Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium

Koivula, Robert W; Franks, Paul W; IMI DIRECT Consortium

doi:10.1007/s00125-019-4906-1

Scientific article

English

Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium

ContributorsKoivula, Robert W; Franks, Paul W; IMI DIRECT Consortium

CollaboratorsVinuela Rodriguez, Ana; Dermitzakis, Emmanouil

Published inDiabetologia, vol. 62, no. 9, p. 1601-1615

Publication date2019

Abstract

Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up).

Keywords

Aged
Biomarkers/blood
Blood Glucose/drug effects/metabolism
Cohort Studies
Diabetes Mellitus
Type 2/blood/drug therapy/epidemiology
Female
Glucose/metabolism
Glucose Tolerance Test
Humans
Male
Metformin/therapeutic use
Middle Aged
Prediabetic State/blood/epidemiology
Prospective Studies

Affiliation entities

Research groups

Population Genomics and Genetics of Complex Traits (892)

Citation (ISO format)

KOIVULA, Robert W, FRANKS, Paul W. Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium. In: Diabetologia, 2019, vol. 62, n° 9, p. 1601–1615. doi: 10.1007/s00125-019-4906-1